---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-349022"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2021-12-06T23:59:59+00:00"
generated_at: "2026-06-28T03:29:25.785838+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Karyopharm director Mikael Dolsten resigns; Peter Honig elected to board

## Summary
- Director Mikael Dolsten resigned effective Dec 2, 2021, citing competing professional demands, no disagreement.
- Peter Honig elected independent director effective Dec 3, 2021, filling a vacancy, Class III term until 2022 annual meeting.
- Honig appointed to Commercialization and Portfolio Committee; awarded option for 47,800 shares at $6.72, vesting over 3 years.

## SEC filing metadata
- accession: 0001193125-21-349022
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2021-12-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312521349022/0001193125-21-349022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312521349022/d203828d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-349022
- JSON: https://secwatch.observer/filing/0001193125-21-349022.json
- Plain text: https://secwatch.observer/filing/0001193125-21-349022.txt

## Key facts
- Executive change
  Mikael Dolsten resigned as Director at Karyopharm Therapeutics Inc..
  - Action: resigned
  - Role: Director
  source text: On December 2, 2021, Mikael Dolsten, MD, PhD, notified Karyopharm Therapeutics Inc. (the “Company”) of his resignation from the Board of Directors (the “Board”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312521349022/0001193125-21-349022-index.htm
- Executive change
  Peter Honig was elected as Director at Karyopharm Therapeutics Inc..
  - Action: elected
  - Role: Director
  source text: On December 3, 2021, the Board, upon the recommendation of the Nominating, Corporate Governance & Compliance Committee of the Board, elected Peter K Honig, M.D., MPH, as an independent director of the Company to fill a vacancy on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312521349022/0001193125-21-349022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.